Assessing the ED Stroke Patient for Disability - What Are the Pitfalls and How to Avoid Them?

December 2, 2020
The NIH Stroke Scale is beneficial when used correctly but is has its limitations. Relying entirely on the NIHSS will miss significant disability in a number of patients. Acute stroke care demands more than just an NIHSS assessment.
0 Comments

What Lessons Have You Learned About Endovascular Therapy in COVID Patients and What Should We All Know?

December 2, 2020
Acute interventional management during the COVID pandemic requires a change of focus and practice. Challenges abound and danger exists at every decision point.
0 Comments

Controversies in Prehospital Medicine: Choosing the Destination Medical Center for Stroke Patients

December 2, 2020
Once a stroke is suspected in the field, it stands to reason that the destination matters for the patient. But how much does it matter and where should patients be taken? Data meets politics in this compelling podcast.
0 Comments

When Might You Use Heparin in the NeuroICU for a Stroke Patient?

December 2, 2020
Heparin in stroke remains controversial. Understanding the history and data and essential to mastering stroke care.
0 Comments

Are the NNT and NNH for tPA Useful or Misleading in Acute Stroke Care?

December 2, 2020
Stroke treatment data are hard to interpret and can be misleading. A lot of misinformation has made its way into the literature and has confounded acute stroke care. Understanding NNT and NNH can help clinicians understand risks and benefits in a meaningful way.
0 Comments
RSS
First12345679
Categories
More Entries

Aug 3

What Is the Clinical Impact of the Genetic Polymorphism Observed with the Effectiveness of some P2Y12 Inhibitors?

Haemin Go posted on 8/3/2021

Moderator:W. Brian Gibler, MD FACEP, FACC, FAHA
Other Participants: Deepak L. Bhatt, MD, MPH and Natalie Kreitzer, MD, MS

Role of genetic polymorphism in TIA and stroke is and has been controversial, since the initial introduction of clopidogrel. Hear Drs. Bhatt and Kreitzer discuss the basics and background associated with the metabolism of the various agents, where we have come, the management of ACSand also for acute ischemic stroke, the role of dual antiplatelet therapy (DAPT), pivotal trials such as THALES, PIVOT, and THEMIS, and the importance of closely monitoring for a recurrent stroke, which happens with high frequency within the 1st month post a stroke.

0 Comments
Please login or register to post comments.